Cefazolin Outperforms Other Antibiotics for MSSA Bacteremia
A study reveals cefazolin significantly reduces treatment failure in adult MSSA bacteremia patients compared to ceftriaxone or piperacillin/tazobactam.

The Cliff News | 19 November 2026
Adult patients battling methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia showed a notably lower risk of treatment failure within 90 days when treated with cefazolin, a retrospective single-center cohort study has found. This finding suggests a potential advantage for cefazolin monotherapy over common alternatives like ceftriaxone or piperacillin/tazobactam.
The observational study aimed to fill a gap in comparative evidence regarding the effectiveness of cefazolin against other antibiotic regimens for this specific infection. Researchers meticulously analyzed clinical data spanning over a decade, offering valuable insights into long-term therapeutic outcomes.
Evaluating Cefazolin's Efficacy
Standard treatment for bloodstream infections caused by MSSA has historically included both cefazolin and antistaphylococcal penicillins. However, direct comparative data on their real-world effectiveness has been limited.
To address this, the study authors conducted a retrospective analysis of adult patients diagnosed with MSSA bacteremia. The patient cohort included individuals who received antimicrobial treatment for confirmed positive blood cultures between January 2010 and December 2022. The final dataset comprised 106 adult patients.
Key Findings on Treatment Failure
The study's primary outcome demonstrated that patients treated with cefazolin experienced a significantly lower incidence of 90-day treatment failure. This suggests that cefazolin may be a more effective choice for clearing MSSA bacteremia and preventing its recurrence or persistence compared to the other agents investigated.
The comparison specifically highlighted the efficacy of cefazolin against ceftriaxone and piperacillin/tazobactam. While these antibiotics are also used for MSSA infections, the current findings point towards cefazolin's superior performance in this patient group over a substantial observational period.
Study Methodology and Implications
This single-center retrospective cohort study provides a critical, albeit localized, perspective on antibiotic choice for MSSA bacteremia. The extended observation period of twelve years allowed for a robust assessment of outcomes under real-world clinical conditions.
The implications of these findings could influence clinical guidelines and prescribing practices for MSSA bacteremia. Further research, potentially including prospective studies, may be warranted to confirm these results across diverse patient populations and healthcare settings.
